反应详情

In a similar manner to that described in example 196, from ethyl 1-(4-fluorophenyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (20 mg, 0.043 mmol) and 2-amino-1-propanol (0.05 mL), was prepared 1-(4-fluorophenyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (8.8 mg, 44% yield) as a white solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.06 (d, J=7.6 Hz, 1 H), 8.53 (s, 1 H), 7.31-7.27 (m, 2 H), 7.22-7.18 (m, 2 H), 7.03-6.93 (m, 4 H), 6.71 (s, 1 H), 4.29 (m, 1 H), 3.95 (s, 2 H), 3.73 (dd, J=10.8, 4 Hz, 1 H), 3.62 (dd, J=10.8, 6.4 Hz, 1 H), 1.26 (d, J=6.8 Hz, 3 H); MS m/z 466 (M+1).